Jincore, a platform company specializing in ultra-small gene editing technology, is promoting the recruitment of experts to commercialize its platform technology following its Series A funding round.
Accordingly, Jincore announced that it appointed Lee Young-pil, former Executive Director of Samsung Bioepis, as co-CEO in December 2022. As a result, Jincore transitioned to a co-CEO system with the existing CEO Kim Yong-sam and the newly appointed CEO Lee Young-pil.
CEO Lee Young-pil has been recognized as a top expert in the field of biopharmaceutical development, having served as Executive Director at Samsung Bioepis after 25 years of experience at LG Life Sciences (now LG Chem Life Sciences Division) and Medytox Co., Ltd.
With the inauguration of Co-CEO Lee Young-pil, Jincore has secured momentum for the development of gene therapies based on ultra-small gene editing technology. A Jincore official stated, “We expect that Co-CEO Lee Young-pil’s decades of accumulated experience and development know-how in the bio industry will accelerate the commercialization of gene therapies.”
Co-CEO Lee Young-pil expressed his aspirations upon taking office, saying, “I hope Jincore grows into a 100-year sustainable company in the bio industry. I will devote my accumulated knowledge and experience to help Jincore become a top player on the global stage.”
Jincore, a research startup founded by Co-CEO Kim Yong-sam in 2019, recently succeeded in raising 17.1 billion KRW in Series A funding, bringing its total accumulated investment to 20.7 billion KRW.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
